Clinical trials for Cushing's syndrome

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Cushing's syndrome. For all clinical trials, go to clinical trials search

This list shows clinical trials for Cushing's syndrome

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Cushing's syndrome
Title Recruitment status Location
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease Recruiting United Kingdom
A study to find out if LCI699 is safe and has beneficial effects in people who have Cushingâ??s disease (CD).CD is caused due to a adenoma (tumor) in the pitutiary gland (Brain) which results in excessive secretion of a hormone (ACTH) causing adrenal glands to secrete excessive cortisol. Recruiting United Kingdom
Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) Recruiting United Kingdom
a study to find out if a drug pasireotide used alone or used with cabergoline together is safe and beneficial for patients with Cushingâ??s disease(Cushingâ??s disease is a condition where the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Recruiting United Kingdom
Treatment for Endogenous Cushing's Syndrome Recruiting United Kingdom
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease Not Recruiting United Kingdom
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Not recruiting United Kingdom
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease Not Recruiting United Kingdom
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease Not Recruiting United Kingdom
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease Not Recruiting United Kingdom

Page last reviewed: 04/02/2015

Next review due: 01/02/2018